In the Phase 3 LIBRETTO-431 study, Retevmo more than doubled progression-free survival (PFS) compared to chemotherapy plus pembrolizumab in patients with advanced or metastatic rearranged during transfection (RET) fusion-positive non-small cell lung cancer (NSCLC)
EIP Pharma to initiate in 2Q 2023 a Phase 2b clinical study, funded in part by a $21 million grant from the National Institute of Aging
The requirement of blood in India is estimated to be 8.5 million to 10 million units/per year, whereas the available supply is only 7.4 million units/per year
Celerity Pharmaceuticals uses Biocon Biologics’ insulin drug substance to develop the product
Ivenix selected Tritan MXF for the pump exterior because of its excellent chemical resistance and durability in the face of the aggressive disinfection protocols needed to prevent the spread of healthcare-associated infections
Capital infusion to accelerate Earendil’s R&D platform
The global, first-in-human, open-label trial will assess the safety, tolerability, pharmacokinetics, and preliminary anti-tumor activity of TRI-611
The framework introduces 15 consensus terms and definitions grouped across four core dimensions of skin health
Previously, Arexvy was authorized for adults 60 and older, and for those 50–59 with heightened risk
The move comes as China rapidly expands its capabilities in the pharmaceutical sector, particularly in licensing and drug development
Subscribe To Our Newsletter & Stay Updated
